Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18

Scientific Reports
Claudia StrossC Welsch

Abstract

High replicative fitness is a general determinant of a multidrug resistance phenotype and may explain lower sensitivity to direct-acting antiviral agents (DAAs) in some hepatitis C virus genotypes. Genetic diversity in the molecular target site of peptidomimetic NS3 protease inhibitors could impact variant replicative fitness and potentially add to virologic treatment failure. We selected NS3 helicase residues near the protease natural substrate in the NS3 domain interface and identified natural variants from a public database. Sequence diversity among different genotypes was identified and subsequently analyzed for potential effects of helicase variants on protein structure and function, and phenotypic effects on RNA replication and DAA resistance. We found increased replicative fitness in particular for amino acid substitutions at the NS3 helicase C-terminal helix α18. A network of strongly coupled residue pairs is identified. Helix α18 is part of this regulatory network and connects several NS3 functional elements involved in RNA replication. Among all genotypes we found distinct sequence diversity at helix α18 in particular for the most difficult-to-treat genotype 3. Our data suggest sequence diversity with implications for...Continue Reading

References

Jul 1, 1997·Reviews in Medical Virology·E DomingoJ J Holland
Dec 11, 1999·Nucleic Acids Research·H M BermanP E Bourne
Mar 23, 2004·Nucleic Acids Research·Robert C Edgar
Jun 3, 2004·Genome Research·Gavin E CrooksSteven E Brenner
Dec 5, 2006·Nucleic Acids Research·Christophe CombetGilbert Deléage
Aug 30, 2008·The Journal of Biological Chemistry·Rudolf K F Beran, Anna Marie Pyle
Sep 19, 2008·Proceedings of the National Academy of Sciences of the United States of America·Volker BrassDarius Moradpour
Aug 12, 2009·Journal of Hepatology·Pierre-Yves BochudUNKNOWN Swiss Hepatitis C Cohort Study Group
Sep 30, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Simone SusserChristoph Sarrazin
May 7, 2010·Science Translational Medicine·Libin RongAlan S Perelson
May 12, 2010·The Journal of Biological Chemistry·Kevin D RaneyCraig E Cameron
Aug 29, 2012·Biochemical and Biophysical Research Communications·Israel Schechter, Arieh Berger
Oct 2, 2012·Nature Chemical Biology·Susanne M Saalau-BethellHarren Jhoti
Aug 10, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kenichi MorikawaDarius Moradpour
Aug 15, 2014·Journal of Virology·Julie SheldonCelia Perales
Apr 22, 2015·Nature Reviews. Gastroenterology & Hepatology·Peter Ferenci

❮ Previous
Next ❯

Citations

Apr 14, 2016·Antimicrobial Agents and Chemotherapy·Isabel GallegoCelia Perales
Apr 14, 2019·Pathogens and Disease·Esteban DomingoCelia Perales
Oct 2, 2019·Cold Spring Harbor Perspectives in Medicine·Keisuke TabataRalf Bartenschlager
Oct 2, 2020·Journal of Clinical Microbiology·María Eugenia SoriaCelia Perales
Apr 4, 2021·Viruses·Hui-Chun LiShih-Yen Lo

❮ Previous
Next ❯

Datasets Mentioned

BETA
EU256082
but

Methods Mentioned

BETA
PCR

Software Mentioned

GraphPad Prism
SEAVIEW
MUSCLE
PyMOL
Chimera

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.